

**Q&A Session for Opioid Settlement Fund Statewide Community Meeting**  
**12.18.24 12:00pm**

Q1. Hello - Regarding the OSFAB website. I am curious if the Commissioner's response to the OSFAB Report has been received and shared? Do you know if an Advisory Board Public Meeting has been scheduled for December?

A1. Information on the Opioid Settlement Fund Advisory board meetings is found here: <https://oasas.ny.gov/opioid-settlement-fund-advisory-board>. The next meeting is 2/27/25.

Q2. Can we receive a breakdown of regional abatement disbursed to each county? Or to just our county?

A2. Information on regional abatement is found on our website: <https://oasas.ny.gov/opioid-settlement-fund-regional-abatements>.

Q3. It is good to see where monies are being spent/allocated, and I would also be interested in the efficacy of the spending focuses to assist with prioritizing and spending. Are you aware of resources for this?

A3. The Opioid Settlement Fund Advisory Board provides recommendations on how funding received by the Opioid Settlement Fund could be allocated. Their reports are available here: <https://oasas.ny.gov/opioid-settlement-fund-advisory-board>.

Q4. Is there a website or resource library where all of the emails and notifications issued by the AG office and/or OASAS related to OSF are catalogued so that agencies or programs that are playing "catch up" on any particular topic (e.g. due to changes in leadership or personnel) can find all of the historic, official communications either from AG office or OASAS?

A4. Information on past and future procurement opportunities related to the Opioid Settlement Fund are available on our website: <https://oasas.ny.gov/opioid-settlement-funding-initiatives>; Information on Opioid Settlement Funds related to Attorney General can be found here: <https://ag.ny.gov/nys-opioid-settlement>.

Q5. As the NPR data speaks highly of NYS OASAS' efforts in utilizing OSF, will there be any attempt on the part of OASAS to document the historic nature of NYS commitment to harm reduction? Would you be open to a proposal from historians documenting the reach of the harm reduction movement in NYS?

A5. OASAS.sm.Communications ([OASAS.sm.Communications@oasas.ny.gov](mailto:OASAS.sm.Communications@oasas.ny.gov)) is the best email to use for more information than what is provided on the website.

Q6. Did OASAS want to share yesterday's Governor office press release? For OISF utilization maybe? "GOVERNOR HOCHUL CONTINUES NEW YORK'S NATION-LEADING EFFORTS TO ADDRESS THE OPIOID AND OVERDOSE CRISIS AND SIGNS NEW LEGISLATION TO KEEP NEW YORKERS SAFE Legislation S.4393/A.5004 Will Increase Access to Fentanyl Test Strips Legislation S.3112-A/A.1588-A Will Require Public Institutions and Buildings of the State to be Equipped With Opioid Antagonists Legislation S.7833-A/A.8467-A Will Authorize Health Care Professionals, Including Pharmacists, to Dispense Drug Adulterant Testing Products That Test for Xylazine."

A6. The press release is available here: <https://www.governor.ny.gov/news/governor-hochul-continues-new-yorks-nation-leading-efforts-address-opioid-and-overdose-crisis>.

Q7. How come we have not explored or awarded funds for programs that focus on a non-narcotic treatment program/Substance programs/pain management non-narcotic treatment programs?

A7. In 2024, Governor Hochul asked the NYS Department of Health to reestablish a pain management working group that first met in 2018, and was halted due to COVID. The Pain Steering Committee will inform best practices, guideline changes, and suggest non-pharmacological ways for patients to cope with pain management. The 2018 committee was invited back as well as new members and includes clinicians from many disciplines. The group is currently prioritizing recommendations for the Department of Health to review as well as the Governor's Office. The workgroup has also asked the Department for several products to assist clinicians in outpatient settings in their use of opioid and non-opioid pain medications as well as the non-pharmacologic management of pain. This is expected to be finalized in 2025.